This case study summarizes how IQVIA Biotech helped a biotechnology company reach critical milestones as it prepared to launch an international Phase III clinical trial for its investigational anaplastic lymphoma kinase (ALK) inhibitor in patients with non-small cell lung cancer (NSCLC).